, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
%). This promising growth was due to more subspecialties as well as capacity expansion. OPD increased by 3 units and IPD increased by 17 units yoy. Number of OPD patients remained on the rise while revenue
revenue streams to mitigate the risk of reliance on sales in China. Currently, the Company received good feedbacks from the market expansion in the Philippines but still could not compensate for the
device sales to decline significantly. The main cause for the decline is the surge in IT devices demand during the COVID-19. Consumers had purchased a large number of IT products such as laptops, tablets
million, and (6) increase in other revenue by 2.43 million. In the first quarter of 2022, sales revenue increased by THB 757.80 million. This surge was primarily driven by Branch and Online sales, a result
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
& vaccination as well as capacity expansion. OPD increased by 4 units and IPD increased by 22 units yoy. OPD income was driven by revenue per head while number of patients (not included outside check-up
by 2.89 million baht or 20.96% of net profit from same period of 2017. The main reason was from an increase in revenue from sales that was changed accordingly in the same direction of the expansion of